BioCentury
ARTICLE | Clinical News

Alpha-gal glycolipids: Phase I data

July 28, 2014 7:00 AM UTC

A Phase I trial in 9 patients with unresectable metastatic melanoma with >=1 resectable cutaneous, subcutaneous or palpable lymph node metastasis showed that 2 intratumoral injections of alpha-gal glycolipids given 4 weeks apart were well tolerated with no dose-limiting toxicities (DLTs) reported. There were 2 cases of stable disease lasting 7 and 8 months, respectively. At 2 and 4 weeks post-injection, target nodules in 5 patients exhibited tumor cell necrosis without neutrophilic or lymphocytic inflammatory responses. Data were presented at the American Society for Clinical Oncology meeting in Chicago. Agalimmune said it plans to evaluate alpha-gal glycolipids in combination with immune checkpoint inhibitors, but did not disclose details. ...